Skip to main content
Clinical Trials/NCT03217292
NCT03217292
Completed
Not Applicable

Evaluation of the Effect of Serratus Anterior Plane Block for Pain Treatment After Video-Assisted Thoracoscopic Surgery

Bursa Yüksek İhtisas Education and Research Hospital0 sites40 target enrollmentJuly 1, 2016

Overview

Phase
Not Applicable
Intervention
Serratus Anterior Plane Block
Conditions
Nerve Block
Sponsor
Bursa Yüksek İhtisas Education and Research Hospital
Enrollment
40
Primary Endpoint
Visual Analogue Scale
Status
Completed
Last Updated
8 years ago

Overview

Brief Summary

Analgesia following video-assisted thoracoscopic surgery (VATS) is important for the prevention of postoperative pulmonary complications.Various regional methods of anesthesia are currently being used to achieve this goal. The aim of the study was to assess the effectiveness of SAPB on postoperative VATS analgesia.

Registry
clinicaltrials.gov
Start Date
July 1, 2016
End Date
December 1, 2016
Last Updated
8 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Bursa Yüksek İhtisas Education and Research Hospital
Responsible Party
Principal Investigator
Principal Investigator

Korgün Ökmen

Principal Investigator

Bursa Yüksek İhtisas Education and Research Hospital

Eligibility Criteria

Inclusion Criteria

  • Patients who were in the American Society of Anesthesiologists (ASA) I-III class and underwent video-assisted thoracoscopic surgery (VATS).

Exclusion Criteria

  • Previous history of opioid use preoperatively,
  • Allergy to local anesthetics,
  • The presence of any systemic infection,
  • Uncontrolled arterial hypertension,
  • Uncontrolled diabetes mellitus.

Arms & Interventions

Group S

IV patient-controlled analgesia (PCA) tramadol+Serratus Anterior Plane Block(SAPB) Tramadol infusion (PCA): 400 mg tramadol, IV 4 mg/mL tramadol solution into 100 mL normal saline; PCA settings: 0.3 mg/kg bolus, 10 mg Demand dose and 20 min lock out interval, six-hour limit infusion to attain 100 mg. Maximum daily dose was set at 400 mg. 20 mL of bupivacaine at a concentration of 0.25% to between serratus anterior and intercostal muscle using the in-line technique for SAPB.

Intervention: Serratus Anterior Plane Block

Group S

IV patient-controlled analgesia (PCA) tramadol+Serratus Anterior Plane Block(SAPB) Tramadol infusion (PCA): 400 mg tramadol, IV 4 mg/mL tramadol solution into 100 mL normal saline; PCA settings: 0.3 mg/kg bolus, 10 mg Demand dose and 20 min lock out interval, six-hour limit infusion to attain 100 mg. Maximum daily dose was set at 400 mg. 20 mL of bupivacaine at a concentration of 0.25% to between serratus anterior and intercostal muscle using the in-line technique for SAPB.

Intervention: IV patient-controlled analgesia (PCA) tramadol

Group T

IV patient-controlled analgesia (PCA) tramadol Tramadol infusion (PCA): 400 mg tramadol, IV 4 mg/mL tramadol solution into 100 mL normal saline; PCA settings: 0.3 mg/kg bolus, 10 mg Demand dose and 20 min lock out interval, six-hour limit infusion to attain 100 mg. Maximum daily dose was set at 400 mg.

Intervention: IV patient-controlled analgesia (PCA) tramadol

Outcomes

Primary Outcomes

Visual Analogue Scale

Time Frame: Postoperative 24 hours

Visual Analogue Scale was used for pain

Secondary Outcomes

  • tramadol consumption(Postoperative 24 hour)
  • Ramsay sedation scale (RSS)(24 hours)

Similar Trials